What is Aqemia?
Aqemia operates at the forefront of pharmaceutical technology, leveraging a unique combination of quantum and statistical mechanics algorithms powered by generative artificial intelligence. This advanced technological approach enables the company to design novel drug candidates at an unprecedented speed. Aqemia has already demonstrated success with several drug discovery initiatives within its internal pipeline and through collaborations with major pharmaceutical companies, positioning itself as a key player in the competitive drug discovery landscape.
How much funding has Aqemia raised?
Aqemia has raised a total of $103M across 2 funding rounds:
Series A
$65M
Other Financing Round
$38M
Series A (2024): $65M with participation from Wendel, Elaia Partners, Bpifrance, and Eurazeo
Other Financing Round (2024): $38M led by Eurazeo, Bpifrance, and Cathay Innovation
Key Investors in Aqemia
Wendel
Wendel Group is an investment firm founded in 1704, headquartered in Paris, France, with a history of international investment in industrial and services companies across various sectors.
Elaia Partners
Elaia Partners is a venture capital firm specializing in supporting tech disruptors from inception to leadership, managing significant assets and focusing on seed to unicorn investments with a strong track record of exits.
Bpifrance
Bpifrance, established in France, provides comprehensive financing solutions including credit, guarantees, and equity to businesses at all stages of development, supporting innovation, international expansion, and export activities.
What's next for Aqemia?
The substantial enterprise-level funding, including the recent strategic investment, signals Aqemia's transition into a scaling phase. This capital will likely be deployed to expand its research and development capabilities, further enhance its AI-driven drug design platform, and potentially broaden its therapeutic focus areas. Strategic partnerships and further clinical development are anticipated as Aqemia aims to bring its innovative drug candidates to market, addressing unmet medical needs across a spectrum of diseases.
See full Aqemia company page
